As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.

Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.